Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In vitro preclinical lead optimisation technologies (PLOTs) in pharmaceutical development.

Christopher K Atterwill1, Mark G Wing

  • 1Huntingdon Life Sciences Ltd, Woolley Road, Alconbury, Cambridgeshire PE28 4HS, UK. sales@ukorg.huntingdon.com

Toxicology Letters
|June 8, 2002
PubMed
Summary

High-throughput screening generates many drug candidates. Lead optimization technologies now help select the best candidates early, improving drug development efficiency and safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel role for Sema3A in neuroprotection from injury mediated by activated microglia.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2006
Same author

Cryopreservation of organotypic brain spheroid cultures.

Alternatives to laboratory animals : ATLA·2004
Same author

Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges.

Molecular biotechnology·2004
See all related articles

Area of Science:

  • Drug discovery and development
  • Preclinical toxicology
  • Pharmacokinetics

Background:

  • High-throughput screening (HTS) generates vast numbers of potential drug candidates.
  • Selecting optimal candidates from HTS presents a significant bottleneck in drug development.
  • Traditional preclinical studies focus on regulatory submission rather than early candidate selection.

Purpose of the Study:

  • To address the challenge of lead candidate selection in drug discovery.
  • To highlight the evolving role of preclinical scientists in optimizing drug candidates.
  • To introduce advancements in preclinical lead optimization technologies.

Main Methods:

  • Lead optimization involves medium-throughput screening of compounds.
  • Absorption, Distribution, Metabolism, Excretion (ADME) and toxicological properties are assessed.

Related Experiment Videos

  • Development of high-throughput toxicity screening approaches.

    • Main Results:

    • Lead optimization facilitates the ranking of compounds based on ADME and toxicity.
    • New preclinical technologies are bridging the gap between efficacy screening and safety assessment.
    • Early identification of promising candidates is becoming more feasible.

    Conclusions:

    • Advancements in preclinical lead optimization are crucial for efficient drug development.
    • Integrating toxicity screening earlier streamlines the selection of viable drug candidates.
    • The role of preclinical science is shifting towards proactive candidate selection and optimization.